Rice Hall James & Associates LLC Buys Shares of 416,631 Aurinia Pharmaceuticals Inc $AUPH

Posted by Brian Himes on Aug 18th, 2026

Rice Hall James & Associates LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 416,631 shares of the biotechnology company’s stock, valued at approximately $7,070,000.

Several other institutional investors and hedge funds have also made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership increased its stake in shares of Aurinia Pharmaceuticals by 213.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after acquiring an additional 2,297,903 shares during the period. Marshall Wace LLP increased its position in shares of Aurinia Pharmaceuticals by 1,272.5% during the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after purchasing an additional 1,375,072 shares during the period. Kotler Kevin bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth $19,536,000. Two Sigma Investments LP raised its stake in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock worth $14,819,000 after buying an additional 1,179,219 shares in the last quarter. Finally, Man Group plc lifted its holdings in shares of Aurinia Pharmaceuticals by 368.9% in the fourth quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock valued at $13,600,000 after buying an additional 670,812 shares during the period. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Trading Down 1.2%

Aurinia Pharmaceuticals stock opened at $15.29 on Tuesday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 6.68 and a beta of 1.42. Aurinia Pharmaceuticals Inc has a 1 year low of $10.34 and a 1 year high of $19.25. The firm’s 50 day moving average price is $15.91 and its two-hundred day moving average price is $15.39. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million during the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. On average, research analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Friday, August 7th. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.67.

Get Our Latest Stock Analysis on Aurinia Pharmaceuticals

Insider Activity

In related news, CEO Kevin Tang bought 206,005 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were bought at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the transaction, the chief executive officer directly owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 814,606 shares of company stock worth $12,455,129 over the last quarter. 10.40% of the stock is owned by insiders.

About Aurinia Pharmaceuticals

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.